Applicant

John E. EDWARDS, Jr. et al.

Appl. No.

09/715,876

Examiner

S. Devi, Ph.D.

Docket No.

13361.4001

IN THE CLAIMS:

1. (Currently Amended) A pharmaceutical composition comprising:
a biocompatible carrier for injection or infusion, and an isolated and purified N-terminal fragment of agglutinin like sequences (ALS1) cell surface adhesion protein (SEQ ID No. <u>8</u> 7) obtained from Candida albicans, wherein the composition produces an effective immune response in a patient.

- 2. (Cancelled)
- 3. (Previously Presented) The composition of Claim 1, wherein the protein contains an adhesion binding site of *Candida albicans*.
 - 4 8. (Cancelled)
- 9. (Currently Amended) The composition of claim 1 wherein the N terminal fragment of the ALS1 protein is encoded by nucleotides 52 to 1296 of the nucleotide sequence of SEQ ID No. 7.
- 10. (Currently Amended) A pharmaceutical composition consisting essentially of:
 a biocompatible carrier for injection or infusion, and an isolated and purified Nterminal fragment of agglutinin like sequences (ALS1) cell surface adhesion protein (SEQ ID NO. 8)
 obtained from Candida albicans, wherein the composition produces an effective immune response in a patient.
- 11. (Previously Presented) The composition of Claim 10 4, wherein the protein contains an adhesion binding site of *Candida albicans*.
- 12. (Currently Amended) The composition of claim 10 4 wherein the N terminal fragment of the ALS1 protein is encoded by nucleotides 52 to 1296 of the nucleotide sequence SEQ ID NOo. 7.

OC-163093.1

2